Behçet’s Disease

Update on the diagnosis and management of Behçet’s disease

Behcet’s Disease has a somewhat “mysterious” prevalence, occurring almost exclusively among peoples originating along the ancient Silk Road.  As such, genetic factors are believed to play a significant role.

While orogenital ulceration is its most common manifestation, ocular and neurological involvements are its most devastating, bringing the patients to clinical presentation.

Various biologics, especially the anti-TNFs, have been found to be highly effective for treating these major complications.

Behçet’s disease in children, an overview

<p><i>Pediatric Rheumatology</i>, the official publication of the Pediatric Rheumatology European Society (PReS), is the leading journal within the subspecialty. The journal publishes clinical and basic research related to pediatric rheumatology and allied subjects. In particular, submissions on the…

Behçet’s disease in children, an overview. For severe manifestations involving the eye, brain or gut, the anti-TNFs are replacing steroids as the standard of care.

The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet’s disease: results of a multicentre open-label study

For refractory Behçet’s uveitis, treatment success has been reported with the following:
1) monoclonal anti-TNFs (Infliximab, Adalimumab, Golimumab);
2) anti-IL6 (Tocilizumab);
3) B-cell depletion (Rituximab).